Lowest Price Guaranteed From USD 5,899
Published
June 2021
Pages
124
View Count
9919
Example Insights
 |
 |
 |
 |
 |
 |
 |
 |
Report Description
The “Porphyria: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Porphyria.
This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product’s mechanism of action, dosage and administration, and pharmacological studies, regulatory milestones, and other development activities.
One of the key objectives of the report was to estimate the existing market size and the future opportunity of therapies for Porphyria, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption of the forecasted therapies and the likely selling price of such therapeutic products, we have provided informed estimates on the evolution of the market for the period 2021-2030.
The “Porphyria Targeting Therapies Market by Type of Drug Class (Biologics and Small Molecules), Type of Porphyria (Acute Hepatic Porphyria, Acute Intermittent Porphyria, Erythropoietic Protoporphyria, Hereditary Porphyria, Porphyria Cutanea Tarda, Variegate Porphyria and X-Linked Protoporphyria), Route of Administration (Oral, Intravenous and Subcutaneous) and Key Geographical Regions (US, Canada, UK, France, Germany, Italy, Spain, Netherlands, Australia and Japan): Industry Trends and Global Forecasts: Industry Trends and Global Forecasts, 2021-2030” report features an extensive study of the current market landscape and future opportunity for the players engaged in developing porphyria targeting therapies. The study presents an in-depth analysis, highlighting the capabilities of various developers engaged in this domain. Amongst other elements, the report features:
One of the key objectives of this report was to estimate the existing market size and to estimate the opportunity associated with the porphyria market We have developed informed estimates on the financial evolution of the market, over the period 2021-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] drug class (biologics and small molecules), [B] route of administration (oral, intravenous and subcutaneous), [C] type of porphyria (Acute Hepatic Porphyria, Acute Intermittent Porphyria, Erythropoietic Porphyria, Hereditary Porphyria, Porphyria Cutanea Tarda, Variegate Porphyria And X-Linked Porphyria) , [D] regional distribution (US, Canada, UK, Germany, France, Italy, Spain, Netherlands, Australia and Japan),. In order to account for future uncertainties and to add robustness to our forecast model, we have provided three scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
1. BACKGROUND
1.1. Context
1.2. Project Report
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. MARKET LANDSCAPE
4.1. Market Landscape of Porphyria Drugs
4.2. Market Landscape of Porphyria Drug Developers
5. CASE STUDY
5.1 Case Study on Terminated and Dormant Programs
6. KEY MARKET INSIGHTS
6.1. Clinical Trial Analysis
6.2. KOL Analysis
6.3. Company Competitiveness Analysis
6.4. Publication Analysis
6.6 Partnership and Collaborations
7. COMPANY PROFILES
7.1. Agios Pharmaceuticals
7.2. Alnylam Pharmaceuticals
7.3. Clinuvel Pharmaceuticals
7.4. Mitsubishi Tanabe Pharma
7.5. Moderna Therapeutics
7.6. Palatin Technologies
7.7. Recordati Rare Diseases
8. MARKET FORECAST
8.1. Drugs Forecasted and Sales Estimated
8.1.1. GIVLAARI®
8.1.2. Panhematin™
8.1.3. SCENESSE®
8.1.4. MT-7117
8.1.5. Colestid
8.1.6. HARVONI®
8.2. Global Market Forecast, Till 2030
8.3. Distribution by Drug Class
8.4. Distribution by Type of Porphyria
8.5. Distribution by Route of Administration
8.6. Distribution by Region
9. APPENDICES
9.1. Clinical Trial Analysis
9.2. Publication Analysis
9.3. List of Figures
9.4. List of Companies and Organizations
9.2. Publication Analysis
9.3. List of Figures
9.4. List of Companies and Organizations
Figure 1.1 Distribution by Phase of Development
Figure 1.2 Distribution by Drug Class
Figure 1.3 Distribution by Phase of Development and Drug Class
Figure 1.4 Distribution by Type of Porphyria
Figure 1.5 Distribution by Type of Porphyria and Phase of Development
Figure 1.6 Distribution by Route of Administration
Figure 1.7 Distribution by Mechanism of Action
Figure 1.8 Distribution by Drug Designation Obtained
Figure 1.9 Distribution by Type of Player and Ownership
Figure 1.10 Distribution by Company Size
Figure 1.11 Distribution by Year of Establishment
Figure 1.12 Players in North America
Figure 1.13 Players in Europe
Figure 1.14 Players in Rest of the World
Figure 1.15 Distribution by Phase of Development and Location of Headquarters
Figure 1.16 Distribution by Type of Molecule and Location of Headquarters
Figure 1.17 Distribution by Phase of Development and Type of Molecule
Figure 3.1 Distribution by Trial Registration Year
Figure 3.2 Distribution by Trial Phase
Figure 3.3 Distribution by Trial Status
Figure 3.4 Analysis by Type of Sponsor
Figure 3.5 Key Industry Players
Figure 3.6 Key Non-industry Players
Figure 3.7 Distribution by Type of Porphyria
Figure 3.8 Distribution by Type of Sponsor and Type of Porphyria
Figure 3.9 Distribution by Trial Status and Type of Porphyria
Figure 3.10 Distribution by Enrolled Patients, Trial Status and Geography
Figure 3.11 Distribution by Trial Status and Geography
Figure 3.12 Distribution of Number of Trials by Geography
Figure 4.1 Distribution by Type of Organization
Figure 4.2 Distribution by Region
Figure 4.3 Distribution by Qualification
Figure 4.4 Distribution by Principal Investigator and Type of Porphyria
Figure 4.5 Distribution by Type of Porphyria
Figure 4.6 KOL Activeness V/S Strength: Scatter Plot
Figure 4.7 Roots Analysis vs Third Party Score
Figure 4.8 Roots Analysis vs Third Party Score
Figure 4.9 Regional Distribution
Figure 4.10 Activeness of KOLs Investigating Drugs in Clinical Studies
Figure 5.1 Benchmarking of Prominent Companies
Figure 5.2 Distribution by Developers
Figure 6.1 Distribution by Year of Publication
Figure 6.2 Distribution by Type of Porphyria
Figure 6.3 Distribution by Type of Porphyria and Year of Publication
Figure 6.4 Key Journals based on Publications Count
Figure 6.5 Word Cloud: Emerging Focus Areas
Figure 6.6 Distribution by Most Popular Authors
Figure 7.1 Distribution by Year of Collaboration
Figure 7.2 Distribution by Type of Collaboration
Figure 7.3 Distribution by Year of Collaboration and Type of Collaboration
Figure 7.4 Distribution by Key Players
Figure 7.5 Key Drugs by Number of Partnerships
Figure 7.6 Intercontinental and Intracontinental Agreements
Figure 9.1 GIVLAARI®: Global Sales Forecast, 2021-2030
Figure 9.2 GIVLAARI®: Regional Sales Forecast, 2021-2030
Figure 9.3 Panhematin®: Global Sales Forecast, 2021-2030
Figure 9.4 Panhematin®: Regional Sales Forecast, 2021-2030
Figure 9.5 SCENESSE®: Global Sales Forecast, 2021-2030
Figure 9.6 SCENESSE®: Regional Sales Forecast, 2021-2030
Figure 9.7 MT-7117: Global Sales Forecast, 2022-20301
Figure 9.8 MT-7117: Regional Sales Forecast, 2022-20301
Figure 9.9 Colestid: Global Sales Forecast, 2022-2030
Figure 9.10 Colestid: Regional Sales Forecast, 2022-2030
Figure 9.11 HARVONI®: Global Sales Forecast, 2025-2030
Figure 9.12 HARVONI®: Regional Sales Forecast, 2025-2030
Figure 9.13 Distribution by Type of Porphyria, 2021
Figure 9.14 Distribution by Type of Porphyria, 2030
Figure 9.15 Acute Hepatic Porphyria: Global Sales Forecast, 2021-2030
Figure 9.16 Acute Hepatic Porphyria: Regional Sales Forecast, 2021-2030
Figure 9.17 AIP: Global Sales Forecast, 2021-2030
Figure 9.18 AIP: Regional Sales Forecast, 2021-2030
Figure 9.19 EPP: Global Sales Forecast, 2025-2030
Figure 9.20 EPP: Regional Sales Forecast, 2021-2030
Figure 9.21 HCP: Global Sales Forecast, 2027-2030
Figure 9.22 HCP: Regional Sales Forecast, 2027-2030
Figure 9.23 PCT: Global Sales Forecast, 2025-2030
Figure 9.24 PCT: Regional Sales Forecast, 2025-2030
Figure 9.25 Variegate Porphyria: Global Sales Forecast, 2027-2030
Figure 9.26 Variegate Porphyria: Regional Sales Forecast, 2027-2030
Figure 9.27 X-Linked Porphyria: Global Sales Forecast, 2024-2030
Figure 9.28 X-Linked Porphyria: Regional Sales Forecast, 2024-2030
Figure 9.29 Distribution by Route of Administration, 2021
Figure 9.30 Distribution by Route of Administration, 2030
Figure 9.31 Oral: Global Sales Forecast, 2022-2030
Figure 9.32 Oral: Regional Sales Forecast, 2022-2030
Figure 9.33 Intravenous: Global Sales Forecast, 2021-2030
Figure 9.34 Intravenous: Regional Sales Forecast, 2021-2030
Figure 9.35 Subcutaneous: Global Sales Forecast, 2021-2030
Figure 9.36 Subcutaneous: Regional Sales Forecast, 2021-2030
Figure 9.37 Overall Market Opportunity, 2021-2030
Figure 9.38 Distribution by Type of Drug Class, 2021, 2025 and 2030
Figure 9.39 Regional Distribution, 2021,2025 and 2030
Figure 9.40 Country-wise Distribution (Bubble Chart Representation)
List Of Companies
The following companies and organizations have been mentioned in the report.
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
YOU MAY ALSO LIKE
SUBSCRIBE TO INDUSTRY UPDATES